fda approval of tirzepatide for weight loss Grants a New Indication Obesity Management Tirzepatide is FDA-approved for weight

Unveiling tirzepatide's therapeutic spectrum: A dual GIP/GLP-1 agonist targeting metabolic, neurological, and cardiovascular health

Tune in to hear Suzy Badaracco, president of Culinary Tides, and Sherry Frey, vice president, Total Wellness, NielsenIQ, in a conversation guided by Michael Costa, managing editor of Food Business News , as they highlight the effect GLP-1 medications are having on consumer packaged goods companies

I help people lose weight in a realistic way and keep it off through personalised coaching and accountability

in @Diagnostics_MDPI: doi.org/10.3390/diagno #Obesity #GLP1 #GIP #Semaglutide #Diagnostics Do Fasting GLP-1 and GIP Levels Predict the Initial Pharmacological Response to Semaglutide and Tirzepatide